Main navigation

• Home
• About us
• Medicines
• Research
• Careers
• Responsibility
• Partnering
• Media
  • Corporate reports
  • Facts, products, pipeline
  • Events calendar
  • Media contacts
  • Press releases
  • Photo library
  • Broadcast Centre
• Investors

You are here

• Home

• Media

Here you will find our corporate press releases, details on upcoming events and other useful information for business and financial media.

• Latest news collapse

  • 19 November 2009 AstraZeneca Submits US New Drug Application for Brilinta (Ticagrelor), an Investigational Antiplatelet Agent

    AstraZeneca today announced it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS). The proposed trade name for ticagrelor is BRILINTA, pending approval from the FDA.

  • 18 November 2009 Results from Two Phase II Trials Add to Understanding of Brilinta (Ticagrelor) and How it Works in the Body

    AstraZeneca today announced the results of the phase II studies, ONSET/OFFSET and RESPOND for ticagrelor (BRILINTA) at the annual American Heart Association (AHA) Scientific Sessions in Orlando, FL, with ONSET/OFFSET study results being simultaneously published in the medical journal Circulation.

  more news

  • previous
  • • 1
    • 2
    • 3
    • 4
    • 5
  • next

  Financial results expand

  Photo & video library collapse

  • Here you can download pictures from our photo library
  • Broadcast footage of AstraZeneca products and activities is available from our Broadcast Centre (requires registration)

• Key Facts collapse

  • We are a world leading pharmaceutical company with a world-class biologics capability.
  • We are active in over 100 countries with a growing presence in important emerging markets including China; corporate office in London, UK; and major R&D sites in Sweden, the UK and the US.
  • We employ over 65,000 people (51% in Europe, 32% in the Americas and 17% in Asia, Africa and Australasia).
  • Alongside our commitment to competitiveness and performance, we continue to be led by our core values to achieve sustainable success.
  • More facts about AstraZeneca

  Research & Development collapse

  We focus our research on six disease areas where we believe our skills and experience can make the most difference.

  • Read about our disease area focus
  • Read about our pipeline progress
  • Review our pipeline summary

Not signed in

Page tools

• Print
• Bookmark this page

Share price